Table 3 Overview of imatinib treatment as of August, 2009 ( n = 575)
Variables | n (%) |
|---|---|
Current imatinib dosage | |
<400 mg/day | 215 (37.4) |
400 mg/day | 335 (58.3) |
>500 mg/day | 22 (3.8) |
No response | 3 (0.5) |
Year of CML diagnosis | |
Before 1990 | 4 (0.7) |
1991 to 1995 | 15 (2.6) |
1996 to 2000 | 68 (11.8) |
2001 to 2005 | 242 (42.1) |
After 2006 | 236 (41.0) |
No response | 10 (1.7) |
Number of patients who were treated with imatinib | |
2000 | 68 (11.8) |
2005 | 284 (49.4) |
2008 | 528 (91.8) |
Frequency of Visits as an Out-patient | |
<1 month | 65 (11.3) |
More than 1 month, but less than 2 months | 320 (55.7) |
More than 2 month, but less than 3 months | 132 (23.0) |
More than 3 month, but less than 4 months | 52 (9.0) |
No response | 6 (1.0) |
Side effects* | |
Facial oedema | 370 (64.3) |
Muscle cramps | 248 (43.1) |
Rash | 235 (40.9) |
Nausea | 214 (37.2) |
Fatigue | 201 (35.0) |
Diarrhoea | 180 (31.3) |
Muscular pain | 141 (24.5) |
Generalised oedema | 136 (23.7) |
Joint pain | 80 (13.9) |
Taste disorder | 67 (11.7) |
Stomach pain | 49 (8.5) |
Other | 137 (23.8) |